Equities research analysts at Leerink Partnrs dropped their Q4 2024 earnings per share estimates for United Therapeutics in a ...

United Therapeutics (UTHR) shares soared 4.9% in the last trading session to close at $370.74. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

It is hard to get excited after looking at United Therapeutics' (NASDAQ:UTHR) recent performance, when its stock has declined 7.4% over the past three months. However, a closer look at its sound ...

United Therapeutics is pioneering a new frontier in organ transplants using pig kidneys. STORY HIGHLIGHTS FDA clears United Therapeutics for human trials of pig-to-human kidney transplants.

United Therapeutics is pioneering a new frontier in organ transplants using pig kidneys. A biotechnology company in Research Triangle Park has taken a major step to develop a new option for ...

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world’s first transplant of ...

The management’s strategic focus on these areas, alongside their ability to efficiently progress through clinical trials, positions United Therapeutics well for substantial growth in the ...

Silver Spring, MD-based United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application ...